Genmab A/S Sponsored ADR (NASDAQ:GMAB) Sees Significant Decrease in Short Interest

Genmab A/S Sponsored ADR (NASDAQ:GMAB) was the recipient of a large decline in short interest during the month of January. As of January 30th, there was short interest totaling 8,413,829 shares, a decline of 15.1% from the January 15th total of 9,908,231 shares. Based on an average daily trading volume, of 2,151,118 shares, the short-interest ratio is currently 3.9 days. Approximately 1.3% of the company’s shares are sold short. Approximately 1.3% of the company’s shares are sold short. Based on an average daily trading volume, of 2,151,118 shares, the short-interest ratio is currently 3.9 days.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the business. Alliancebernstein L.P. lifted its position in Genmab A/S by 2.7% in the 3rd quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock valued at $335,957,000 after acquiring an additional 291,538 shares in the last quarter. Orbis Allan Gray Ltd lifted its holdings in shares of Genmab A/S by 38.7% in the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after purchasing an additional 2,209,659 shares in the last quarter. Paradigm Biocapital Advisors LP purchased a new position in shares of Genmab A/S during the third quarter valued at approximately $117,063,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Genmab A/S by 5.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock valued at $111,735,000 after buying an additional 188,761 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Genmab A/S by 23.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock worth $107,580,000 after buying an additional 671,307 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

GMAB has been the topic of several analyst reports. Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Truist Financial restated a “buy” rating and issued a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. HC Wainwright reiterated a “buy” rating and set a $39.00 price target on shares of Genmab A/S in a report on Wednesday, January 28th. Finally, Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.33.

Genmab A/S Stock Up 1.5%

Shares of NASDAQ:GMAB opened at $30.03 on Monday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $35.43. The stock’s 50 day moving average is $32.35 and its 200-day moving average is $29.76. The firm has a market capitalization of $19.29 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 17.63 and a beta of 0.90.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.